David Kirn, 4DMT CEO
FDA lifts hold on 4DMT's Fabry gene therapy
The FDA lifted an 18-month clinical hold on 4D Molecular Therapeutics’ cardiomyopathy gene therapy for Fabry disease.
The biotech said Thursday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
